Join
Live feed
·
PRReleasevia Quantisnow
Forte Biosciences Inc. logo
argenx SE logo

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

ByQuantisnow·Wall Street's wire, on your screen.
FBRX· Forte Biosciences Inc.ARGX· argenx SE
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FBRX (Forte Biosciences Inc.), ARGX (argenx SE) and more on Quantisnow.